Accelerated access to medicines

an ethical analysis

Jessica Pace*, Narcyz Ghinea, Ian Kerridge, Wendy Lipworth

*Corresponding author for this work

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In recent years, a range of initiatives have been introduced to provide patients with access to medicines outside of traditional regulatory and/or funding channels; we term these processes “accelerated access to medicines.” These generally take 1 of 3 forms: those that provide access by making existing regulatory and funding processes more efficient, those that provide access despite uncertainties surrounding safety or efficacy, and those that provide access despite uncertainties surrounding cost-effectiveness. These latter 2 types are the subject of intense debate, as they generally require us to suspend or override accepted standards of evidence of safety, effectiveness, and/or cost-effectiveness. Ethical analysis provides valuable insights into these debates and highlights the risks and benefits that may accrue as a consequence of different accelerated access schemes. In this article, we use the principle-based approach to ethical analysis described by Beauchamp and Childress (sometimes called the “four principles approach” because it frames analysis by reference to beneficence, non-maleficence, autonomy, and justice) to analyze initiatives that provide accelerated access to medicines. We identify a number of ethical issues that may arise in the context of accelerated access initiatives, including potential patient harms, impacts on patient autonomy and informed consent, and effects on research and regulatory systems. The complex ethical issues at play emphasize that there is no single answer to questions as to whether such schemes are “ethical”; rather, ethical principles will need balancing, context will be critically important, and discussion among the various stakeholder groups will be needed to reach an “ethically good” outcome.

Original languageEnglish
Pages (from-to)157-163
Number of pages7
JournalTherapeutic Innovation and Regulatory Science
Volume51
Issue number2
DOIs
Publication statusPublished - 2017
Externally publishedYes

Keywords

  • bioethics
  • pharmaceutical regulation
  • pharmaceutical funding decisions
  • coverage with evidence development
  • investigational drugs

Fingerprint Dive into the research topics of 'Accelerated access to medicines: an ethical analysis'. Together they form a unique fingerprint.

Cite this